Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 24, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Betamethasone Valerate Foam, 0.12%".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 24, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Betamethasone Valerate Foam, 0.12%".